

Maria Danila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2034333/publications.pdf>

Version: 2024-02-01

49
papers

1,989
citations

516215

16
h-index

264894

42
g-index

51
all docs

51
docs citations

51
times ranked

4234
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 2.	1.6	6
2	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2022, 74, 1049-1057.	1.5	10
3	COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. <i>Arthritis and Rheumatology</i> , 2022, 74, 1091-1092.	2.9	9
4	Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. <i>Arthritis Care and Research</i> , 2022, 74, 733-740.	1.5	16
5	Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210835.	1.2	30
6	Healthcare disparities in telemedicine for rheumatology care. <i>Current Opinion in Rheumatology</i> , 2022, 34, 171-178.	2.0	6
7	Integration of stakeholder engagement from development to dissemination in genomic medicine research: Approaches and outcomes from the CSER Consortium. <i>Genetics in Medicine</i> , 2022, 24, 1108-1119.	1.1	5
8	Education and Training of Non-Genetics Providers on the Return of Genome Sequencing Results in a NICU Setting. <i>Journal of Personalized Medicine</i> , 2022, 12, 405.	1.1	13
9	Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study. <i>ACR Open Rheumatology</i> , 2022, 4, 279-287.	0.9	1
10	Telemedicine in rheumatology care: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 56, 152045.	1.6	21
11	Satisfaction with Telerheumatology Care: Patient and Clinician Perspectives. , 2022, , 251-261.		1
12	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021, 48, 603-607.	1.0	56
13	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021, 3, 17-24.	0.9	10
14	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021, 3, 381-389.	0.9	19
15	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1523-1532.	2.9	30
16	The Development of the Rheumatology Informatics System for Effectiveness Learning Collaborative for Improving Patient-Reported Outcome Collection and Patient-Centered Communication in Adult Rheumatology. <i>ACR Open Rheumatology</i> , 2021, 3, 690-698.	0.9	5
17	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161.	1.5	32
18	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 933-941.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventions. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100474.	0.5	20
20	Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 826-841.	0.9	6
21	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 478-487.	3.1	13
22	Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use. <i>Research in Social and Administrative Pharmacy</i> , 2020, 17, 1267-1275.	1.5	0
23	Lessons learned about harmonizing survey measures for the CSER consortium. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 537-546.	0.3	16
24	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
25	A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 345-353.	0.3	65
26	Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. <i>Osteoporosis International</i> , 2020, 31, 1283-1290.	1.3	6
27	Genetic influences on susceptibility to rheumatoid arthritis in African-Americans. <i>Human Molecular Genetics</i> , 2019, 28, 858-874.	1.4	55
28	Pragmatic Clinical Trials in Osteoporosis. <i>Current Osteoporosis Reports</i> , 2019, 17, 521-526.	1.5	2
29	Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States. <i>Journal of Rheumatology</i> , 2019, 46, 237-244.	1.0	3
30	IFN γ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation. <i>ELife</i> , 2019, 8, .	2.8	116
31	Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 763-772.	3.1	27
32	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 40-44.	1.0	32
33	Improving drug adherence in osteoporosis: an update on more recent studies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 141-149.	1.2	28
34	A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults. <i>Innovation in Aging</i> , 2018, 2, igy013.	0.0	4
35	Advancing the Science and Practice of Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018, 33, 216-222.	1.3	57
36	Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. <i>Osteoporosis International</i> , 2017, 28, 2495-2503.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Dense Genotyping of Immune-Related Regions Identifies Loci for Rheumatoid Arthritis Risk and Damage in African Americans. <i>Molecular Medicine</i> , 2017, 23, 177-187.	1.9	18
38	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 128-137.	0.3	8
39	A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 14-24.	0.5	13
40	Simple regression for correcting $\hat{\Gamma}$ Ct bias in RT-qPCR low-density array data normalization. <i>BMC Genomics</i> , 2015, 16, 82.	1.2	15
41	The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis. <i>Genes and Immunity</i> , 2015, 16, 446-451.	2.2	8
42	Measurement of Erythrocyte Methotrexate Polyglutamate Levels: Ready for Clinical Use in Rheumatoid Arthritis?. <i>Current Rheumatology Reports</i> , 2010, 12, 342-347.	2.1	28
43	Recent advances in personalizing rheumatoid arthritis therapy and management. <i>Personalized Medicine</i> , 2009, 6, 159-170.	0.8	8
44	Update on pathogenic mechanisms of systemic necrotizing vasculitis. <i>Current Rheumatology Reports</i> , 2008, 10, 430-435.	2.1	12
45	Pharmacogenetics of etanercept in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2008, 9, 1011-1015.	0.6	23
46	Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. <i>Rheumatology</i> , 2008, 48, 542-545.	0.9	169
47	Biologics and heart failure in rheumatoid arthritis: are we any wiser?. <i>Current Opinion in Rheumatology</i> , 2008, 20, 327-333.	2.0	35
48	The Effectiveness of Fracture Liaison Services in Improving Fragility Fracture Outcomes. <i>Current Treatment Options in Rheumatology</i> , 0, , 1.	0.6	0
49	Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey. <i>Rheumatology Advances in Practice</i> , 0, , .	0.3	9